New teriparatide studies find bone gains vary by setting

The kidney findings concern denser bone, while evidence about safety and fracture prevention remains limited.¹ The 2026 review searched for trials that assigned treatments by chance in adults with advanced kidney disease, including kidney transplant recipients.¹ It found only two eligible trials, leaving a small evidence base for its conclusions. PubMed

One analysis covered just 5 participants with severely reduced kidney function, rather than an entire trial devoted to that group.¹ Teriparatide increased bone density at the lower spine and the upper thigh bone in that subgroup.¹ The other trial included 61 people receiving dialysis, a treatment that filters the blood when kidney function is severely impaired.¹ Its teriparatide group had greater bone-density gains at the hip than the comparison group. PubMed

Reported unwanted health events were more frequent in the teriparatide group.¹ The abstract does not give their types or the size of that difference.¹ The limitation is that gains at selected bone sites, alongside these limited safety details, do not establish the overall benefit for people with advanced kidney disease. PubMed

The dental findings come from animals, not from trials showing that implants last longer in people.² The 2026 review searched for studies published between January 2015 and August 2025 involving animals with osteoporosis, a condition that weakens bones.² It examined whether teriparatide improved how surrounding bone grew against and attached to dental implants.² Researchers assessed tissue samples, detailed scans, and tests of mechanical stability. PubMed

Across the included animal studies, intermittent treatment improved bone measurements around implants.² Some combinations with other experimental treatments also outperformed teriparatide alone in those models.² However, the studies differed substantially in their design, measurements, and quality, limiting efforts to combine their findings into an overall estimate.² The limitation is that this animal evidence does not yet establish better implant survival or a dependable benefit in people. PubMed

The mouse study found that a response in one bone did not reliably describe the response elsewhere in the skeleton.³ Published in 2027, it examined male and female mice from eight genetically different strains after four weeks of intermittent treatment.³ The researchers measured bone density, bone structure, and strength using scans and mechanical testing. PubMed

Some strains responded at the thigh bone but not the spine, while others showed the reverse pattern.³ Genetic background influenced several measurements, with the strongest inherited influence appearing in the amount of inner, sponge-like bone.³ These findings support studying bone sites separately rather than assuming that one measurement captures the whole response. PubMed

The way bone changed also differed by sex.³ Male mice tended to expand the outer surface of the thigh bone, while females showed changes along its inner surface.³ The limitation is that these patterns explain variation within the mouse experiment, not which individual people will benefit from teriparatide. PubMed

These studies examine different questions, so their positive findings should not be treated as repeated proof of the same benefit.¹ The kidney review examines human bone density, the implant review examines local bone attachment in animals, and the mouse experiment examines differences in response.¹ Their measures overlap in bone growth, but their populations and practical implications remain distinct. PubMed+2

Earlier osteoporosis research provides direct evidence about fractures, which is a different outcome from a denser scan.⁴ A review published in 2004 described a trial involving 1,637 women whose treatments were assigned by chance.⁴ Over 18 months, teriparatide reduced new spine fractures by 65% and fractures elsewhere by 35% compared with placebo, an inactive comparison treatment.⁴ Those percentages describe fewer fractures, rather than only changes in bone density. Wiley

Kidney-specific research has a much smaller history.¹ A 2010 pilot study involving 7 people receiving dialysis reported improved lower-spine bone density in adynamic bone disease, a condition in which bone renewal is unusually slow.⁵ The newer review adds trial evidence, but its two eligible trials still leave uncertainty about effectiveness and safety in advanced kidney disease. PubMed

Another human trial shows why density gains do not necessarily mean fewer fractures in a different condition.⁶ In 2026, a trial involving 349 people with osteogenesis imperfecta, an inherited condition that makes bones fragile, tested teriparatide plus another bone drug against standard care.⁶ Bone density increased, but fractures occurred in 36.9% of the treatment group and 36.4% of the standard-care group, with no reduction in fractures.⁶ The limitation is that this result concerns a distinct inherited disorder, but it reinforces the need to measure fractures rather than infer them from density alone. JAMA Network

For advanced kidney disease, larger studies are still needed to establish fracture outcomes and define safety more clearly.¹ For dental implants, the missing step is dependable human trial evidence showing whether the animal findings translate into better outcomes.² For differences linked to sex and genetic background, the mouse study does not provide a validated way to predict a person's response.³ The new research broadens where bone gains have been observed, but it does not make those gains interchangeable with fewer fractures or longer-lasting implants. PubMed+2